Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai Ups April-Sept. Profit Forecasts on Lower Sales
October 1, 2015
- Asahi Kasei Pharma Seek Japan Approval of Once-Yearly Osteoporosis Drug
October 1, 2015
- Astellas Licenses Analgesic Ion Channel Blocker from US Chromocell
October 1, 2015
- Fujifilm to Establish Cellular Dynamics Japan for iPS Biz
September 30, 2015
- CMIC Holdings CEO to Double as OrphanPacific Chairman
September 30, 2015
- Halaven Now under FDA’s Priority Review for Soft Tissue Sarcoma: Eisai
September 30, 2015
- Janssen Seeks Pediatric Use for Ultiva in Japan
September 30, 2015
- Amgen Astellas Building Sales Force before PCSK9 Approval
September 29, 2015
- GSK to Compensate for Add’l Patient Burdens Tied to Hep B Drug Shortage
September 29, 2015
- Takeda Files Nesina-Metformin Combo Drug in Japan
September 29, 2015
- Celgene Launches Japan PI for Pleiotropic Pathway Modifier
September 29, 2015
- Chugai to Create New Post to Gear Up for HTA Introduction
September 28, 2015
- Maruho Files NDA for Japan’s First Infantile Hemangioma Treatment
September 28, 2015
- MEDINET Partners with Univ. of Tokyo in Joint Research for iPS Immuno-Cell Therapy
September 28, 2015
- Nihon Generic to Build New Factory with 10 Billion-Tablet Capacity
September 25, 2015
- MTPC, MedImmune Hook Up on Antibody Drug Conjugates
September 25, 2015
- NICE Recommends New Lixiana Indication for Health Coverage: Daiichi Sankyo
September 25, 2015
- Taiho Gets FDA Nod for Lonsurf, Its First Approval in US
September 25, 2015
- Terumo Aims at Annual Sales of 1-2 Billion Yen for HeartSheet within 5-10 Years
September 25, 2015
- Achieving New Share Target for Generics Will Be “Quite Difficult”: Hengrui Japan President
September 25, 2015
ページ
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…